Mizoribine Market Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast – 2022 to 2028

The mizoribine market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Mizoribine is an immunosuppressant drug; the growing demand for organ transplants and the increase in the number of autoimmune disorders are the main factors contributing to the growth of the mizoribine market. According to the NCBI, mizoribine is used to treat patients with kidney transplants, IgA and nephropathy, lupus erythematosus, childhood nephrotic syndrome (NS), and others this is evaluated the efficacy of mizoribine oral treatment for severe lupus nephritis, NS-resistant NS, as well as frequent relapses. -S NS-dependent steroids, used in these medicines the demand for mizoribine rapidly increased. For instance, in 2018, according to the WHO, nearly 91,800 kidney transplant procedures, around 6,200 lung transplants, and about 30,800 liver transplants took place and some prominent companies around the globe are making efforts to leverage the rise in organ transplant procedures, that boosts the growth of the market during the forecast period.

The increase in the prevalence of the immunosuppressant disease has created a demand for the development of new drugs for its treatment which in turn drives the global mizoribine market growth. In addition, leading pharmaceutical companies are focusing on the development of drugs for mizoribine treatment. The market growth is driven by the strong focus of the pharmaceutical companies and research organizations on the R&D of drugs for mizoribine drugs, creating a strong pipeline for effective therapy. However, immunosuppressant drugs cause side effects, adversely affecting their need and this is a major factor that hinders market growth of mizoribine.

In April 2019, GlaxoSmithKline PLC announced the USFDA approval for their newly developed intravenous (IV) formulation of Benlysta. The approval of this new formulation means that children in the US would now have access to this FDA-approved, newly developed medication to control the effects of lupus. Such type of drug approval is further anticipated to drive the global mizoribine market.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape-GlaxoSmithKline PLC, Glenmark Pharmaceuticals, Inc., Hoffmann-La Roche AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Mizoribine Market Report by Segment

By Type

• 30 Tablets Packaging
• 48 Tablets Packaging
• 100 Pieces of Packaging

By Application

• Arthritis
• Lupus Nephritis
• Nephrotic Syndrome
• Immunosuppressant
• Liver Transplantation
• Other